Authorised Indian Distributor
Saxsons Group
New Delhi, India · Since 1997
No-carrier-added Lutetium-177 (produced by SHINE Medical, supplied across India by Saxsons) paired with PSMA-617 (vipivotide tetraxetan) for targeted radionuclide therapy in metastatic castration-resistant prostate cancer. The VISION-trial protocol — n.c.a. starting material, ≥99.9 % radionuclidic purity, AERB-importable, delivered cold-chain across India.
| Radionuclide | Lutetium-177 (Lu-177) |
| Production route | No-carrier-added (n.c.a.) reactor production |
| Half-life | 6.647 days |
| Decay mode | β⁻ (max 498 keV); γ 113 keV (6.4%), 208 keV (11%) |
| Specific activity | n.c.a. — highest available (TBq/mg) |
| Chemical form | Lutetium chloride in dilute HCl |
| Radionuclidic purity | ≥ 99.9% (Ph. Eur. compliant) |
| Radiochemical purity | Tested post-labelling; typical ≥ 98% |
| Clinical indication | PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) |
| Labelling target | PSMA-617 (vipivotide tetraxetan) |
| Therapy sessions | Up to 6 cycles; 7.4 GBq per cycle (standard) |
| Quality release | Certificate of Analysis per batch; GMP documentation |
| AERB status | Import licence required; Saxsons manages regulatory documentation |
Targeted theranostics — one isotope, imaging and therapy
FDA/EMA-approved treatment backbone for metastatic castration-resistant prostate cancer. Lu-177 PSMA-617 delivers targeted β-radiation to PSMA-expressing tumour cells.
Paired with Ga-68 or F-18 PSMA PET for theranostic cycle planning and inter-cycle response assessment. Same PSMA target — one for imaging, one for therapy.
n.c.a. Lu-177's high specific activity enables individualised dosimetry with SPECT/CT using the 208 keV gamma photon — tumour and organ dose quantification between cycles.
Consistent n.c.a. batches support comparative dosimetry research, novel PSMA-targeting peptide development and multi-centre theranostic clinical trials.
Emerging combination data with PARP inhibitors and AR-targeted agents. n.c.a. purity required for mechanistic studies of radiosensitisation.
Investigational use in PSMA-positive salivary gland carcinoma, renal cell carcinoma and other PSMA-overexpressing solid tumours.
Carrier-added Lu-177 dilutes specific activity, lowering PSMA-617 labelling efficiency and increasing non-specific radiation dose. n.c.a. Lu-177 achieves the highest labelling yields and lowest cold-metal content — the clinical standard for PSMA therapy.
GMP certification covers the full production chain — target irradiation, chemical separation, formulation, QC and release. Every shipment carries batch release documentation for AERB compliance and hospital pharmacy acceptance.
Saxsons coordinates cold-chain import, AERB licensing, customs clearance and same-day hospital delivery on therapy day. Your radiopharmacist receives ready-to-label Lu-177 — no logistics burden on the department.
SHINE product page for the upstream Lu-177 n.c.a. starting material. Contact Saxsons for AERB import documentation, cold-chain scheduling and PSMA-617 peptide kit pairing.
Lu-177 + PSMA-617
Each card opens a focused post for a specific specialty — peer-reviewed evidence and clinical workflow, written for the persona you select.
For Nuclear-Medicine Physician
VISION eligibility, the PSMAfore line-of-therapy shift, and the salivary-gland and kidney dose ceilings that bound the six-cycle ¹⁷⁷Lu-PSMA-617 course.
Read this Nuclear-Medicine PhysicianThe salivary-gland dose ceiling, not tumour response, sets the six-cycle stopping criterion. Why ≥ 3,000 GBq/mg, ≥ 99.9 % RNP and ≥ 99 % RCP are what the VISION protocol chemistry actually requires.
Read thisContact Saxsons Group for supply agreements, AERB import documentation and dosimetry support for your Lu-177 + PSMA-617 therapy programme in India.